List view / Grid view
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
1 December 2015 | By Victoria White
U3 Pharma is a clinical-stage biopharmaceutical company developing protein therapeutics for the treatment of diseases with serious unmet need, primarily cancer...
1 October 2015 | By Victoria White
The TaNeDS programme provides close partnership between successful applicants and scientists in Daiichi Sankyo to tackle unmet medical needs...
7 May 2015 | By Victoria White
Plexxikon and MSD have announced a collaborative clinical trial that will evaluate the combination of PLX3397 and KEYTRUDA in melanoma...
11 November 2014 | By Daiichi Sankyo Company
Daiichi Sankyo Company, Limited announced that it has selected research partners for its 2014 TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project...
30 September 2014 | By Daiichi Sankyo
Lead compound, Quizartinib, will further build Daiichi Sankyo oncology pipeline...
18 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar1, in rheumatoid arthritis (the RApsody trial) in Japan...
7 August 2014 | By Daiichi Sankyo
...to develop and commercialize novel, fixed-dose combination hydrocodone products for pain and opioid-induced nausea and vomiting in the US.
27 May 2014 | By Daiichi Sankyo
Dainippon Sumitomo Pharma Co., Ltd. and Daiichi Sankyo Co., Ltd. announced that they have entered into a license agreement for the commercialization of lurasidone hydrochloride...
22 May 2014 | By Daiichi Sankyo
Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co., Ltd. announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases...
3 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Co., Ltd. and University of California, San Francisco announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases...
19 March 2014 | By Daiichi Sankyo
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
14 February 2014 | By Daiichi Sankyo Company
Norovirus is one of the leading causes of infectious gastroenteritis and the number of infected people reported is increasing both in Japan and globally...
